Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025)

Oramed Pharmaceuticals has reported Gross Margin for 7 years, with the latest figure at 0.65% in Q1 2025.

• For the quarter ending Q1 2025, Gross Margin changed N/A year-over-year to 0.65%; the trailing twelve-month figure through Dec 2025 stood at 0.65% (changed N/A YoY), and the FY2025 full-year result was 0.65%, changed N/A from the prior year.
• Gross Margin for Q1 2025 stood at 0.65%, down from 71.51% in the prior quarter.
• The five-year high for Gross Margin was 72.37% in Q1 2023, with the low at 0.65% in Q1 2025.
• Historically, Gross Margin has averaged 38.61% across 3 years, with a median of 37.87% in 2022.
• The largest YoY upside for Gross Margin was 6096 bps in 2023 against a maximum downside of 2789 bps in 2023.
• Oramed Pharmaceuticals' Gross Margin stood at 32.11% in 2022, then jumped by 123 bps to 71.51% in 2023, then tumbled by 99 bps to 0.65% in 2025.
• The last three Gross Margin figures came in at 0.65% (Q1 2025), 71.51% (Q2 2023), and 72.37% (Q1 2023), per Business Quant data.